Research progress of the methods for predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma treatment / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
; (12): 632-636, 2023.
Article
en Zh
| WPRIM
| ID: wpr-993385
Biblioteca responsable:
WPRO
ABSTRACT
In recent years, immune checkpoint inhibitors (ICIs) have emerged as a significant advancement in the treatment of advanced hepatocellular carcinoma (HCC), providing benefits to a subset of patients. At present, there are still many problems with ICIs treatment for HCC, such as limited objective remission rate, high treatment cost, frequent treatment-related adverse events, and tumor hyperprogression. In this context, it is important to find indicators that can predict the efficacy of ICIs treatment in order to optimize patients’ selection and maximize clinical benefits, further avoiding unnecessary toxic side effects and economic losses. This article discusses biochemical and cytological indicators, tumor-related markers, imaging indicators, and immune-related adverse events in order to guide clinical treatment.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Hepatobiliary Surgery
Año:
2023
Tipo del documento:
Article